Cargando…

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults

Background Long-term persistence of immune response and safety of two doses of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based Adjuvant System) administered 21 d apart was evaluated in Japanese adults [NCT00989612]. Methods On...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikematsu, Hideyuki, Nagai, Hideaki, Kawashima, Masahiro, Kawakami, Yasunobu, Tenjinbaru, Kazuyoshi, Li, Ping, Walravens, Karl, Gillard, Paul, Roman, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367709/ https://www.ncbi.nlm.nih.gov/pubmed/22426369 http://dx.doi.org/10.4161/hv.18469

Ejemplares similares

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
por: Nagai, Hideaki, et al.
Publicado: (2010)

Evaluation of immune response following one dose of an AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies
por: Garcia-Sicilia, José, et al.
Publicado: (2015)

Long-term booster schedules with AS03(A)-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
por: Gillard, Paul, et al.
Publicado: (2014)

Non‐neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system
por: Friel, Damien, et al.
Publicado: (2020)

Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study
por: Gillard, Paul, et al.
Publicado: (2014)

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
por: van der Most, Robbert G., et al.
Publicado: (2017)

IF-03 Clinical Effectiveness of Oseltamivir or Zanamivir for Influenza A/H1N1 Virus with or without H274Y Mutation
por: Kawai, Naoki, et al.
Publicado: (2009)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
por: Launay, Odile, et al.
Publicado: (2013)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination
por: Galson, J. D., et al.
Publicado: (2016)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination
por: Díez-Domingo, Javier, et al.
Publicado: (2015)

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec
por: Montplaisir, Jacques, et al.
Publicado: (2014)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England
por: Winstone, Anne Marie, et al.
Publicado: (2014)

Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk
por: Vaarala, Outi, et al.
Publicado: (2014)

Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
por: Madsen, Anders, et al.
Publicado: (2021)

An FAQ dataset for E-learning system used on a Japanese University
por: Sumikawa, Yasunobu, et al.
Publicado: (2019)

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
por: Heijmans, Stéphane, et al.
Publicado: (2011)

Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine
por: Puleston, Richard, et al.
Publicado: (2013)

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
por: Nolan, Terry, et al.
Publicado: (2014)

HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children
por: Leahy, Timothy R, et al.
Publicado: (2014)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
por: Dos Santos, Gaël, et al.
Publicado: (2017)

Cortaillod 21.1.03 Techmeta 26.03.03 CMS SUPRA
Publicado: (2003)

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10
por: Uphoff, Helmut, et al.
Publicado: (2011)

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()
por: Yang, William H., et al.
Publicado: (2013)

Principal contribution of HLA-DQ alleles, DQB1*06:04 and DQB1*03:01, to disease resistance against primary biliary cholangitis in a Japanese population
por: Yasunami, Michio, et al.
Publicado: (2017)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
por: Howard, Leigh, et al.
Publicado: (2018)

Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66(®) cell culture platform
por: Endo, Masafumi, et al.
Publicado: (2020)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland
por: Nohynek, Hanna, et al.
Publicado: (2012)

HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study
por: Miki, Daiki, et al.
Publicado: (2013)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014)

AS03 stresses out macrophages: Commentary on ‘Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties’
por: Orr, Mark T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mi49j0mnqoikqa2br58hrvdabk